A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

被引：0
|
作者：
Qu, J. [1 ]
Liu, L. [2 ]
Heng, J. [2 ]
Zhou, C. [2 ]
Xiong, Y. [2 ]
Jiang, W. [2 ]
Yang, N. [2 ]
机构：
[1] Hunan Prov Canc Hosp, Dept Lung Canc & Gastroenterol, Changsha, Hunan, Peoples R China
[2] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] A phase IIIb, open-label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis
    Rosell, R.
    Poltoratskiy, A.
    Hochmair, M.
    Laktionov, K. K.
    Ramlau, R.
    Alonso Garcia, M.
    Skrickova, J.
    Piovano, P. L.
    Rizzato, S.
    Bidoli, P.
    Kowalski, D.
    Clementi, L.
    Cseh, A.
    De Marinis, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
    Zheng, Qian
    Lin, Xue
    Qi, Wenli
    Yin, Jun
    Li, Juan
    Wang, Ye
    Wang, Weiya
    Li, Weimin
    Liang, Zongan
    LUNG CANCER, 2024, 194
  • [43] Clinical outcomes of patients with advanced EGFR mutation positive (EGFRm) non-small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib resistance: A multicentre retrospective study
    Chen, O. H.
    Kam, T. Y.
    Du, Q.
    Nyaw, S. F.
    Chik, Y. K.
    Cheung, A. H.
    Chow, C.
    Chan, L. L.
    Yan, K. C. K.
    Mok, K.
    Wong, W.
    Tsui, G.
    Chen, C. C. A.
    Mok, T. S. K.
    Li, S. C. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1663 - S1663
  • [44] EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study
    Helland, A.
    Andersen, K. K.
    Myklebust, T. A.
    Johannesen, T. B.
    Hallerback, T.
    Enerly, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S889 - S889
  • [45] HIGH EXPRESSION OF C-MET WITH WIDE TYPE EGFR MUTATION IDENTIFY A DISTINCT SUBSETS INDICATIVE POOR PROGNOSIS IN PATIENTS WITH NSCLC
    Huang, Ling
    An, She J.
    Chen, Zhi H.
    Su, Jian
    Xie, Zhi
    Yan, Hong H.
    Zhang, Xu C.
    Huang, Ying
    Chen, Shi L.
    Guo, Wei B.
    Wu, Yi-long
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S470 - S470
  • [46] Concurrent EGFR-TKI and Thoracic Radiation Therapy as 1st-Line Treatment of Stage IV NSCLC Patients Harboring EGFR Active Mutation (CERTAIN study)
    Sun, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E709 - E709
  • [47] Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
    Long, Jianlin
    Lei, Shuangyi
    Wu, Zhijuan
    Xiong, Shuanglong
    Wang, Chunmei
    Huang, Lumi
    Liang, Guanzhong
    Yang, Dan
    Teng, Yan
    Li, Yongsheng
    Qi, Jun
    Li, Dairong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [48] EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
    Helland, Aslaug
    Andersen, Klaus Kaae
    Myklebust, Tor age
    Johannesen, Tom Borge
    Aaroe, Jorgen
    Enerly, Espen
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [49] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C. Ta
    Soo, R.
    Yang, J.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S59 - S60
  • [50] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R. Rasim
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S37 - S37
12345